Convertible Debenture Sample Contracts

Greater Cannabis Company, Inc. – Allonge to Convertible Debenture Due September 14, 2018 (April 17th, 2018)

This Allonge ("Allonge") is made as of March 28, 2018, by The Greater Cannabis Company, Inc., a Florida corporation ("Borrower") to Emet Capital Partners LLC ("Holder"). Reference is hereby made to that certain Convertible Note Due September 14, 2018 issued by Borrower to Holder dated September 14, 2017 ("Debenture"). Except as amended hereby, the terms of the Debenture remain as originally stated. Terms not otherwise defined herein shall have the meaning set forth in the Debenture.

American Funeral Svcs Corp – Amendment to Convertible Debenture (April 17th, 2018)

THIS AMENDMENT TO CONVERTIBLE DEBENTURE (the "Amendment") is dated as of [__], 2018 and shall be deemed to be made effective as of June 30, 2017 (the "Effective Date") by and between Eight Dragons Company, a Nevada corporation (the "Company" or "Eight Dragons") and [__] (the "Holder"). Each of the Company and Holder may be referred to herein individually as a "Party" and collectively as the "Parties."

Ample-Tee, Inc. – Airborne Wireless Network Convertible Debenture (April 13th, 2018)

FOR VALUE RECEIVED, AIRBORNE WIRELESS NETWORK, a Nevada corporation (the "Company"), hereby promises to pay to the order of YA II PN, LTD., or its registered assigns (the "Holder") the amount set out above as the Principal Amount (as reduced pursuant to the terms hereof pursuant to redemption, conversion or otherwise, the "Principal") on the Maturity Date (as defined below) or upon the earlier of acceleration, redemption or otherwise (in each case in accordance with the terms hereof) and to pay interest ("Interest") on any outstanding Principal at the applicable Interest Rate from the date set out above as the Debenture Issuance Date (the "Issuance Date") until the same becomes due and payable on the Maturity Date or upon the earlier of acceleration, conversion, redemption or otherwise (in each case in accordance with the terms hereof). This Convertible Debenture (the "Debenture") was originally issued pursuant to the Securities Purchase Agreement dated as of April 9, 2018, (the "Secur

Micronet Enertec Technologies, Inc. – MICRONET ENERTEC TECHNOLOGIES, INC. ENERTEC ELECTRONICS LTD. Secured Convertible Debenture (April 4th, 2018)

This Secured Convertible Debenture is issued in exchange for the secured note originally issued on [_________]2 in the outstanding principal amount of $[________] are was acquired for consideration consisting solely of the [___________] surrendered for cancellation in the exchange.

Neurokine Pharmaceuticals Inc. – Pivot Pharmaceuticals Inc. (Formerly Known as Neurokine Pharmaceuticals Inc.) 10.00% Senior Secured Convertible Debenture Due March 2, 2019 (March 12th, 2018)

PIVOT PHARMACEUTICALS INC. (formerly known as Neurokine Pharmaceuticals Inc.), a corporation incorporated under the laws of British Columbia (the "Borrower"), for value received, hereby acknowledges itself indebted and promises to pay to or to the order of Investor Company ITF 5J5712 Anson Catalyst Master Fund LP, 77 Bloor Street West, 3rd Floor, Toronto, Ontario M5S 1M2 as nominee for Anson Catalyst Master Fund LP as nominee for Anson Catalyst Master Fund LP (hereinafter referred to as the "Lender" or the "Debentureholder"), the principal amount of two million five hundred thousand dollars ($2,500,000) (the "Principal Amount") in lawful money of Canada in the manner hereinafter provided at the foregoing address of the nominee, or at such other place or places as the Lender may designate by notice in writing to the Borrower, on March 2, 2019, or such earlier date as the Principal Amount may become due and payable (the "Maturity Date"), and to pay interest to the Lender on the Principal

Neurokine Pharmaceuticals Inc. – Pivot Pharmaceuticals Inc. (Formerly Known as Neurokine Pharmaceuticals Inc.) 10.00% Senior Secured Convertible Debenture Due March 2, 2019 (March 12th, 2018)

PIVOT PHARMACEUTICALS INC. (formerly known as Neurokine Pharmaceuticals Inc.), a corporation incorporated under the laws of British Columbia (the "Borrower"), for value received, hereby acknowledges itself indebted and promises to pay to or to the order of Investor Company ITF 5J5636 Anson Investments Master Fund LP, 77 Bloor Street West, 3rd Floor, Toronto, Ontario M5S 1M2 as nominee for Anson Investments Master Fund LP (hereinafter referred to as the "Lender" or the "Debentureholder"), the principal amount of two million five hundred thousand dollars ($2,500,000) (the "Principal Amount") in lawful money of Canada in the manner hereinafter provided at the foregoing address of the nominee, or at such other place or places as the Lender may designate by notice in writing to the Borrower, on March 2, 2019, or such earlier date as the Principal Amount may become due and payable (the "Maturity Date"), and to pay interest to the Lender on the Principal Amount outstanding from time to time o

Biolabmart Inc. – First Amendment to 8% Convertible Debenture: (March 2nd, 2018)

This First Amendment to the 8% Convertible Debenture dated September 1, 2016 made by BioLabMart Inc., now known as Qrons Inc. (the "Company") for the benefit of CubeSquare LLC in the amount of $10,000 (the "Debenture") hereby amends the Debenture as follows:

CollPlant Holdings Ltd. – Convertible Debenture (January 23rd, 2018)

THIS CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued Convertible Debentures of CollPlant Holdings Ltd., a company organized under the laws of the State of Israel (the Company), having its principal place of business at 3 Sapir Street, Weizmann Science Park, Ness-Ziona 74140 Israel, designated as its Convertible Debenture due (this debenture, the Debenture and, collectively with the other debentures of such series, the Debentures).

CollPlant Holdings Ltd. – Convertible Debenture Due December 31, 2022 (January 23rd, 2018)

THIS CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued Convertible Debentures of CollPlant Holdings Ltd., a company organized under the laws of the State of Israel (the Company), having its principal place of business at 3 Sapir Street, Weizmann Science Park, Ness-Ziona 74140 Israel, designated as its Convertible Debenture due December 31, 2022 (this debenture, the Debenture and, collectively with the other debentures of such series, the Debentures).

CollPlant Holdings Ltd. – Convertible Debenture Due October 26, 2022 (January 23rd, 2018)

THIS CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued Convertible Debentures of CollPlant Holdings Ltd., a company organized under the laws of the State of Israel (the Company), having its principal place of business at 3 Sapir Street, Weizmann Science Park, Ness-Ziona 74140 Israel, designated as its Convertible Debenture due October 26, 2022 (this debenture, the Debenture and, collectively with the other debentures of such series, the Debentures).

ADVANCED MEDICAL ISOTOPE Corp – Agreement to Amend Senior Secured Convertible Debenture Maturing May 9, 2018 in the Original Principal Amount of $[______] (December 18th, 2017)

This Agreement is made as of December 13, 2017, and shall amend that certain Secured Convertible Debenture dated May [__], 2017 in the principal amount of $[______] issued by Advanced Medical Isotope Corporation, a Delaware corporation (the Company") to [_________] (the "Holder") (the "Note").

Lion Consulting Group – CANTABIO PHARMACEUTICALS INC. Secured Convertible Debenture (November 27th, 2017)

FOR VALUE RECEIVED, CANTABIO PHARMACEUTICALS INC., a Delaware corporation (the "Company"), hereby promises to pay to the order of YA II PN, Ltd., or its registered assigns (the "Holder") the amount set out above as the Principal Amount (as reduced pursuant to the terms hereof pursuant to redemption, conversion or otherwise, the "Principal") when due, whether upon the Maturity Date (as defined below), acceleration, redemption or otherwise (in each case in accordance with the terms hereof) and to pay interest ("Interest") on any outstanding Principal at the applicable Interest Rate from the date set out above as the Original Issuance Date (the "Issuance Date") until the same becomes due and payable, whether upon an Interest Date (as defined below), the Maturity Date or acceleration, conversion, redemption or otherwise (in each case in accordance with the terms hereof). This Secured Convertible Debenture (including all debentures issued in exchange, transfer or replacement hereof, this "D

Incorporated Under the Canada Business Corporations Act 10.00%, Subject to Adjustment, Amended and Restated Secured Convertible Debenture Due January 12, 2020 (November 14th, 2017)

This Debenture is issued upon the terms and conditions, including redemption and conversion, as are set out in Schedule "A" hereto, and the terms, conditions and provisions contained in Schedule "A", including its appendices are incorporated herein and constitute a part hereof. Unless the context otherwise requires, capitalized expressions herein shall have the meaning ascribed to them in Schedule "A" hereto.

Series [A-1] [A-2] 12.5% Senior Secured Convertible Debenture (October 27th, 2017)

THIS SERIES [A-1] [A-2] 12.5% SENIOR SECURED CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued 12.5% Senior Secured Convertible Debentures of Social Reality, Inc., a Delaware corporation (the Company), having its principal place of business at 456 Seaton Street, Los Angeles, CA 90013, designated as its 12.5% Senior Secured Convertible Debenture due April 21, 2020 (this debenture, the Debenture and, collectively with the other debentures of such series, the Debentures). This Debenture is one of a series Debentures issued pursuant to the terms of the Purchase Agreement (as that term is hereinafter defined).

Convertible Debenture Due October 2, 2047 (October 11th, 2017)

THIS CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued Convertible Debentures of Rosetta Genomics Ltd., an Israeli corporation (the "Company"), having its principal place of business at 10 Plaut Street, Science Park, Rehovot 76706, Israel, designated as its Convertible Debenture due October 2, 2047 (this debenture, the "Debenture" and, collectively with the other debentures of such series, the "Debentures").

ResortHealthcare – Series a Convertible Debenture (September 15th, 2017)

This Debenture is free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Borrower and will not impose personal liability upon the holder thereof.

20% Original Issue Discount Unsecured Convertible Debenture Due on or Before November 30, 2017 (August 29th, 2017)

THIS 20% ORIGINAL ISSUE DISCOUNT UNSECURED CONVERTIBLE DEBENTURE, dated as of June 5, 2017 between the "Holder" (defined below) and PROTEA BIOSCIENCES GROUP, INC., a Delaware corporation (the "Company"), having its principal place of business at 1311 Pineview Drive, Suite 501, Morgantown, WV 26505 (the "Exchange Agreement").

EpiCept Corporation – Original Issue Discount Convertible Debenture (August 24th, 2017)

THIS ORIGINAL ISSUE DISCOUNT CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued Original Issue Discount Convertible Debentures of Immune Pharmaceuticals, Inc., a Delaware corporation, (the "Company"), having its principal place of business at 550 Sylvan Avenue, Englewood Cliffs, NJ 07632, designated as its Original Issue Discount Convertible Debenture due on the Maturity Date (as defined below) (this debenture, the "Debenture" and, collectively with the other debentures of such series, the "Debentures").

Extension of Maturity Date of Convertible Debenture (August 11th, 2017)

This Extension of Maturity Date of Convertible Debenture ("Extension") is by and between the individual or entity named on an executed counterpart of the signature page hereto (each such signatory is referred to as "Holder") and OmniComm Systems, Inc., a Delaware corporation ("Maker") and is entered into as of the day the last Holder executes a copy of this Extension.

ADVANCED MEDICAL ISOTOPE Corp – 7.5% ORIGINAL ISSUE DISCOUNT SENIOR SECURED CONVERTIBLE DEBENTURE DUE May _____, 2018 (August 11th, 2017)

THIS 7.5% ORIGINAL ISSUE DISCOUNT SENIOR SECURED CONVERTIBLE DEBENTURE of ADVANCED MEDICAL ISOTOPE CORPORATION, a Delaware corporation, (the "Company"), having its principal place of business at 719 Jadwin Avenue, Richland, WA 99352, designated as its 7.5% Original Issue Discount Senior Secured Convertible Debenture due May ___, 2018 (the "Debenture"). This Debenture is being issued in connection with that certain Exchange Agreement pursuant to which the Company exchanged certain then outstanding indebtedness that was issued by the Company on November 2, 2016 for this Debenture.

ADVANCED MEDICAL ISOTOPE Corp – 7.5% Original Issue Discount Senior Secured Convertible Debenture Due May , 2018 (August 11th, 2017)

THIS 7.5% ORIGINAL ISSUE DISCOUNT SENIOR SECURED CONVERTIBLE DEBENTURE of ADVANCED MEDICAL ISOTOPE CORPORATION, a Delaware corporation, (the "Company"), having its principal place of business at 719 Jadwin Avenue, Richland, WA 99352 designated as its 7.5% Original Issue Discount Senior Secured Convertible Debenture due May 9, 2018 (the "Debenture"). This Debenture is being issued in connection with that certain Exchange Agreement pursuant to which the Company exchanged certain then outstanding indebtedness that was issued by the Company on November 2, 2016 for this Debenture.

ADVANCED MEDICAL ISOTOPE Corp – 7.5% Original Issue Discount Senior Secured Convertible Debenture Due May , 2018 (May 15th, 2017)

THIS 7.5% ORIGINAL ISSUE DISCOUNT SENIOR SECURED CONVERTIBLE DEBENTURE of ADVANCED MEDICAL ISOTOPE CORPORATION, a Delaware corporation, (the "Company"), having its principal place of business at 719 Jadwin Avenue, Richland, WA 99352 designated as its 7.5% Original Issue Discount Senior Secured Convertible Debenture due May 9, 2018 (the "Debenture"). This Debenture is being issued in connection with that certain Exchange Agreement pursuant to which the Company exchanged certain then outstanding indebtedness that was issued by the Company on November 2, 2016 for this Debenture.

ADVANCED MEDICAL ISOTOPE Corp – 7.5% ORIGINAL ISSUE DISCOUNT SENIOR SECURED CONVERTIBLE DEBENTURE DUE May ___, 2018 (May 15th, 2017)

THIS 7.5% ORIGINAL ISSUE DISCOUNT SENIOR SECURED CONVERTIBLE DEBENTURE of ADVANCED MEDICAL ISOTOPE CORPORATION, a Delaware corporation, (the "Company"), having its principal place of business at 719 Jadwin Avenue, Richland, WA 99352, designated as its 7.5% Original Issue Discount Senior Secured Convertible Debenture due May ___, 2018 (the "Debenture").

EpiCept Corporation – Original Issue Discount Convertible Debenture (May 15th, 2017)

THIS ORIGINAL ISSUE DISCOUNT CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued Original Issue Discount Convertible Debentures of Immune Pharmaceuticals, Inc., a Delaware corporation, (the " Company "), having its principal place of business at 430 East 29th Street, Suite 940, New York, New York 10016, designated as its Original Issue Discount Convertible Debenture due on the Maturity Date (as defined below) (this debenture, the " Debenture " and, collectively with the other debentures of such series, the " Debentures ").

ADVANCED MEDICAL ISOTOPE Corp – 7.5% ORIGINAL ISSUE DISCOUNT SENIOR SECURED CONVERTIBLE DEBENTURE DUE May _____, 2018 (May 15th, 2017)

THIS 7.5% ORIGINAL ISSUE DISCOUNT SENIOR SECURED CONVERTIBLE DEBENTURE of ADVANCED MEDICAL ISOTOPE CORPORATION, a Delaware corporation, (the "Company"), having its principal place of business at 719 Jadwin Avenue, Richland, WA 99352, designated as its 7.5% Original Issue Discount Senior Secured Convertible Debenture due May ___, 2018 (the "Debenture"). This Debenture is being issued in connection with that certain Exchange Agreement pursuant to which the Company exchanged certain then outstanding indebtedness that was issued by the Company on November 2, 2016 for this Debenture.

First Amendment to Convertible Debenture (May 15th, 2017)

This First Amendment to the Convertible Debenture (the "First Amendment") is entered into as of May 11, 2017 by and among Tauriga Sciences, Inc., a Florida corporation (the "Company") and Group 10 Holdings LLC ("Holder") or its registered assigns or successor in interest. The Company and Holder each referred to herein as a "Party" or collectively as the "Parties".

First Amendment to Convertible Debenture (May 15th, 2017)

This First Amendment to the Convertible Debenture (the "First Amendment") is entered into as of May 11, 2017 by and among Tauriga Sciences, Inc., a Florida corporation (the "Company") and Group 10 Holdings LLC ("Holder") or its registered assigns or successor in interest. The Company and Holder each referred to herein as a "Party" or collectively as the "Parties".

First Amendment to Convertible Debenture (May 15th, 2017)

This First Amendment to the Convertible Debenture (the "First Amendment") is entered into as of May 11, 2017 by and among Tauriga Sciences, Inc., a Florida corporation (the "Company") and Group 10 Holdings LLC ("Holder") or its registered assigns or successor in interest. The Company and Holder each referred to herein as a "Party" or collectively as the "Parties".

EpiCept Corporation – Original Issue Discount Convertible Debenture (May 10th, 2017)

THIS ORIGINAL ISSUE DISCOUNT CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued Original Issue Discount Convertible Debentures of Immune Pharmaceuticals, Inc., a Delaware corporation, (the "Company"), having its principal place of business at 430 East 29th Street, Suite 940, New York, New York 10016, designated as its Original Issue Discount Convertible Debenture due on the Maturity Date (as defined below) (this debenture, the "Debenture" and, collectively with the other debentures of such series, the "Debentures").

Lion Consulting Group – Secured Convertible Debenture (May 5th, 2017)

FOR VALUE RECEIVED, CANTABIO PHARMACEUTICALS INC., a Delaware corporation (the "Company"), hereby promises to pay to the order of [-------------], or its registered assigns (the "Holder") the amount set out above as the Principal Amount (as reduced pursuant to the terms hereof pursuant to redemption, conversion or otherwise, the "Principal") when due, whether upon the Maturity Date (as defined below), acceleration, redemption or otherwise (in each case in accordance with the terms hereof) and to pay interest ("Interest") on any outstanding Principal at the applicable Interest Rate from the date set out above as the Original Issuance Date (the "Issuance Date") until the same becomes due and payable, whether upon an Interest Date (as defined below), the Maturity Date or acceleration, conversion, redemption or otherwise (in each case in accordance with the terms hereof). This Secured Convertible Debenture (including all debentures issued in exchange, transfer or replacement hereof, this "

Boston Therapeutics, Inc. – 6% Subordinated Convertible Debenture Due 2018 (May 2nd, 2017)

THIS 6% SUBORDINATED CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued 6% Subordinated Convertible Debentures of Boston Therapeutics, Inc., a Delaware corporation, (the "Company"), having its principal place of business at 354 Merrimack Street, #4, Lawrence, MA 01843, designated as its 6% Subordinated Convertible Debenture due 2019 (this debenture, the "Debenture" and, collectively with the other debentures of such series, the "Debentures"). The terms not defined herein shall have the meaning as set forth in the Purchase Agreement.

Solitario Resources Corporation – Convertible Debenture of Zazu Metals Corporation (May 1st, 2017)

Article 1 INTERPRETATION 6 1.1 Definitions 6 1.2 Meaning of Outstanding 8 1.3 Non-Business Days 8 1.4 Currency 9 1.5 Headings 9 1.6 Governing Law 9 1.7 Singular, Gender, Legislation, Etc. 9 1.8 Severability 9 1.9 Binding Effect 9 1.10 Time 9 Article 2 The debenture 10 2.1 Indebtedness. 10 2.2 Calculation and Payment of Interest, etc. 10 2.3 Non-Transferable 10 2.4 Prepayment 10 Article 3 CONVERSION OF DEBENTURE 11 3.1 Conversion Privilege and Conversion Price 11 3.2 Conversion Procedure 11 3.3 No Fractional Shares 11 3.4 Adjustment to Conversion Price 12 3.5 Certificate as to Adjustment 14 3.6 Reclassifications, Reorganizations, etc. 14 3.7 Notice to Debentureholder of Cert

mLight Tech, Inc. – MLIGHT TECH, INC. Series a CONVERTIBLE DEBENTURE DUE: April 18, 2018 (April 24th, 2017)

FOR VALUE RECEIVED, the undersigned, MLIGHT TECH, INC. (herein called the "Company"), a Florida corporation, promises to pay to the order HE CEN, or his or its registered assigns (the "Holder" or "Holders"), the principal sum of one hundred and fifty thousand dollars (US$150,000), as such amount is reduced pursuant to the terms hereof pursuant to redemption, conversion or otherwise (the "Principal"), on April 18, 2018 (the "Maturity Date"), together with interest (computed on the basis of a 365-day year) on the outstanding principal amount at the rate of eight percent (8%) per annum (the "Interest Rate") from the date hereof, payable on June 30, 2017 and, thereafter, quarterly in arrears, until the principal hereof shall have become due and payable.

Form of 12.5% Secured Convertible Debenture (April 21st, 2017)

THIS 12.5% SENIOR SECURED CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued 12.5% Senior Secured Convertible Debentures of Social Reality, Inc., a Delaware corporation, (the Company), having its principal place of business at 456 Seaton Street, Los Angeles, CA 90013, designated as its 12.5% Senior Secured Convertible Debenture due _____, 2020 (this debenture, the Debenture and, collectively with the other debentures of such series, the Debentures). This Debenture is one of a series Debentures issued pursuant to the terms of the Purchase Agreement (as that term is hereinafter defined).

20% Amended and Restated Original Issue Discount Unsecured Convertible Debenture Due September 30, 2017 (April 14th, 2017)

THIS AMENDED AND RESTATED 20% ORIGINAL ISSUE DISCOUNT UNSECURED CONVERTIBLE DEBENTURE amends and restates in it entirety a duly authorized and validly issued 20% Original Issue Discount Unsecured Convertible Debenture (the "Original Debenture") of PROTEA BIOSCIENCES GROUP, INC., a Delaware corporation, (the "Company"), having its principal place of business at 1311 Pineview Drive, Suite 501, Morgantown, WV 26505, designated as its 20% Original Issue Discount Unsecured Convertible Debenture due on a date that was six (6) months from the Original Issue Date